Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504776 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
A Phase 1 study of Mantle Cell Lymphoma, sponsored by Anand Jillella.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT01504776: Completed Phase 1 study of Mantle Cell Lymphoma, sponsored by Anand Jillella.
NCT01504776 is a Phase 1 study of Mantle Cell Lymphoma that has completed, run by Anand Jillella. The registered enrollment target is 3 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01504776, a Phase 1 study of Mantle Cell Lymphoma, has completed, sponsored by Anand Jillella.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
Primary Outcome
To determine the DLTs and MTD of panobinostat given in combination with bortezomib.
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG Panobinostat
Study Locations (1)
Georgia
- Georgia Regents University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT01504776 record still lists
NCT01504776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.
NCT01504776 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT01504776 about?
NCT01504776 is a clinical study titled "Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)". The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
What is the current status of trial NCT01504776?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-04. Estimated completion is 2014-09.
What conditions does trial NCT01504776 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma.
What interventions are being tested in trial NCT01504776?
The interventions under investigation include: Bortezomib (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT01504776?
This trial is sponsored by Anand Jillella, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01504776 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01504776's enrollment target sits among peer trials
3 103rd of 102 the lowest of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia